Table 1 Patient characteristics in the overall population and according to baseline plasma EGFR mutation status.

From: Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients

Characteristics

All

(N = 89)

Undetectable ctEGFR

(N = 44)

Detectable ctEGFR CqMut-high (N = 21)

Detectable ctEGFR CqMut-low (N = 24)

P-values

Age at diagnosis, n (%)

 Median (IQR)

67 (59–74)

68 (60–75)

67 (58.5–72.5)

66 (56–72)

0.64

 < 60 years

24 (27%)

10 (22.7%)

7 (33.3%)

7 (29.2%)

 ≥ 60 years

65 (73%)

34 (77.3%)

14 (66.7%)

17 (70.8%)

Gender, n (%)

 Male

31 (34.8%)

13 (29.5%)

7 (33.3%)

11 (45.8%)

0.40

 Female

58 (65.2%)

31 (70.5%)

14 (66.7%)

13 (54.2%)

ECOG PS, n (%)

 0–1

76 (85.4%)

38 (86.4%)

20 (95.2%)

18 (75%)

0.15

 ≥ 2

13 (14.6%)

6 (13.6%)

1 (4.8%)

6 (25%)

Smoking status, n (%)

 Never

66 (74.2%)

33 (75%)

14 (66.7%)

19 (79.2%)

0.62

 Current/former

23 (25.8%)

11 (25%)

7 (33.3%)

5 (20.8%)

Histology, n (%)

 Adenocarcinoma

83 (93.3%)

42 (95.5%)

20 (95.2%)

21 (87.5%)

0.42

 NSCLC NOS

6 (6.7%)

2 (4.5%)

1 (4.8%)

3 (12.5%)

Number of metastatic sites, n (%)

 < 3 sites

59 (66.3%)

34 (77.3%)

15 (71.4%)

10 (41.7%)

0.01*

 ≥ 3 sites

30 (33.7%)

10 (22.7%)

6 (28.6%)

14 (58.3%)

 Brain metastasis, n (%)

22 (24.7%)

10 (22.7%)

5 (23.8%)

7 (29.2%)

0.84

 Liver metastasis, n (%)

22 (24.7%)

8 (18.2%)

3 (14.3%)

11 (45.8%)

0.02*

EGFR mutation subtypes, n (%)

 Del19

53 (59.6%)

24 (54.5%)

15 (71.4%)

14 (60.9%)

0.68

 L858R

30 (33.7%)

16 (36.4%)

5 (23.8%)

9 (37.5%)

 Uncommona

6 (6.7%)

4 (9.1%)

1 (4.8%)

1 (4.2%)

Line of EGFR TKIs, n (%)

 First line

85 (95.5%)

42 (95.5%)

20 (95.2%)

23 (95.8%)

0.99

 Later line

4 (4.5%)

2 (4.5%)

1 (4.8%)

1 (4.2%)

Type of EGFR TKIs, n (%)

 Gefitinib or Erlotinib

83 (93.3%)

40 (90.9%)

21 (100%)

22 (91.7%)

0.37

 Afatinib

2 (2.2%)

1 (2.3%)

0

1 (4.2%)

 Osimertinib

4 (4.5%)

3 (6.8%)

0

1 (4.2%)

Duration of TKI treatment, median (IQR, months)

10.5 (6.6–14.1)

12.8 (7.0-15.9)

11.0 (7.9–13.5)

6.8 (3.6–11.6)

0.48

ORR, n (%)

46 (67%)

17 (55%)

13 (81%)

16 (73%)

0.09

  1. aUncommon EGFR mutations, including G719X in exon 18 (n = 2), de novo T790M in exon 20 (n = 1), L861G or Q in exon 21 (n = 2) and complex mutation (n = 1). Del19: exon 19 deletion, ECOG PS: Eastern Cooperative Oncology Group performance status, EGFR: epidermal growth factor receptor, IQR: interquartile range, ORR: overall response rate.
Back to article page